Clinical Trials on Usher Syndrome Type 1C

Total 3174 results

Celgene

Terminated

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Canada, Norway, Spain, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome

United States
University of Chicago

Terminated

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of Campinas, Brazil

Unknown

Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Brazil
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Leukemia | Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Dana-Farber Cancer Institute
Eli Lilly and Company

Terminated

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
St. Jude Children's Research Hospital

Terminated

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
GWT-TUD GmbH

Terminated

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (SAMBA)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

France, Germany
M.D. Anderson Cancer Center
Centocor, Inc.

Completed

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Nantes University Hospital

Completed

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (VIDAZA-DLI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease
Genzyme, a Sanofi Company
AnorMED

Withdrawn

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia
National University Hospital, Singapore
Singapore General Hospital

Unknown

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Singapore
Riverside Haematology Group

Unknown

Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United Kingdom
M.D. Anderson Cancer Center
Sanofi

Terminated

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

United States
Kyowa Kirin, Inc.

Terminated

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United Kingdom
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.; Celgene Corporation

Active, not recruiting

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of Nebraska

Active, not recruiting

ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
University Hospital Freiburg

Active, not recruiting

Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood (EWOG MDS 2006)

Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia

Germany
University of Birmingham
Jazz Pharmaceuticals; Adienne SA; IMPACT (funded by NHS Blood & Transplant, Anthony...

Active, not recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (COSI)

Acute Myeloid Leukaemia | High-risk Myelodysplastic Syndrome

United Kingdom
University of Rochester

Active, not recruiting

A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Daiichi Sankyo, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Grupo Cooperativo de Hemopatías Malignas

Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Mexico
Jonsson Comprehensive Cancer Center

Withdrawn

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia
Aileron Therapeutics, Inc.

Completed

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Unknown

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
Dartmouth-Hitchcock Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
Biosuccess Biotech Co., Ltd.

Terminated

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome (AML/MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Hoffmann-La Roche

Completed

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Shanghai Tong Ren Hospital

Unknown

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company; Eisai Inc.

Completed

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Sheba Medical Center

Completed

TevaGastrim for Stem Cell Mobilization Sibling Donors

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
University of Pittsburgh

Completed

Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States, Canada, Australia
University of Chicago

Completed

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States

Clinical Trials on Usher Syndrome Type 1C

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations